July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Retinopathy of Prematurity in Rwanda: setting up a screening system.
Author Affiliations & Notes
  • Stefan Karel De Smedt
    Ophthalmology, AZ St Maarten Hospital, Mechelen, Belgium
    Ophthalmology, Institute of Tropical Medicine, Antwerp, Belgium
  • Footnotes
    Commercial Relationships   Stefan De Smedt, None
  • Footnotes
    Support  Hoffknecht Van Vuure Stichting (The Netherlands), Vision for All (Switzerland), Rotary Club Overijse Zonienwoud (Belgium), Lions Club Heerlijkheid Mechelen (Belgium), Lumos University Hospitals Leuven (Belgium), NGO Umubano-Impore (Rwanda), Théa Pharma
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 186. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Stefan Karel De Smedt; Retinopathy of Prematurity in Rwanda: setting up a screening system.. Invest. Ophthalmol. Vis. Sci. 2018;59(9):186.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Retinopathy of Prematurity (ROP) increasingly threatens the vision of premature babies in low income countries, where ophthalmic screening has to catch up with improving neonatal care. Little is known about its incidence in sub-Saharan Africa. We introduced a ROP screening program in Rwanda with an explorative case control study nested in a prospective observational study to document ROP incidence and risk factors in the 3 major neonatal intensive care units (NICU).

Methods : All neonates admitted to the NICUs from September 2015 till July 2017 were recruited, if fulfilling the inclusion criteria (gestational age (GA) <35 weeks or birth weight (BW) <1800 grams or unstable clinical course). The incidence of mild and treatment requiring ROP (Zone I, stage 3 without plus disease or Zone I, any stage with plus disease, or Zone II, Stage 2 and 3 with plus disease) were studied. Risk factors for ROP were analyzed in univariate and multivariate logistic regression models, calculating odds ratios (OR) with 0.05 significance tests and 95% confidence intervals (CI).

Results : Among 2240 babies admitted to the NICUs, 802 (35,8%) fulfilled the inclusion criteria, of which 424 were screened for ROP and analyzed (12 refusals, 271 deaths, 95 losses to follow-up prior to eye check). The mean GA (± standard deviation SD, range) was 31.68 weeks (SD 2.16, 24-37). The mean BW was 1480grams (SD 360, 650-2800). A total of 31 babies (7.31%, CI 5.02-10.22) developed any ROP and 14 (3.3%, CI 1.82-5.48) required treatment. ROP was seen in 6 babies with GA >30 weeks and BW >1500 grams, of which 3 required treatment. Univariate analysis identified as ROP risk factors: high oxygen (O2) supply (OR 2.20, p<0.001, CI 1.54-3.15), low BW (OR 2.25, p<0.001, CI 1.48-3.41), low GA (OR 3.41, p<0.001, CI 1.81-6.41), hyperglycemia ≥150mg/dl (OR 6.63, p<0.001, CI 2.04-21.50), blood transfusion (OR 3.04, p=0.002, CI 1.44-6.43) and sepsis (OR 3.23, p= 0.01, CI 1.20-8.66). After multivariate analysis O2 supply (OR 2.05, p=0.01, CI 1.18-3.57) and hyperglycemia (OR 3.48, p=0.05, CI 0.98-12.35) remained significant.

Conclusions : In Rwanda the incidence of treatment requiring ROP is in the same range as in Western literature, but ROP screening is indicated beyond the 2013 American Academy screening guidelines. Especially O2 supply and hyperglycemia deserve special attention. Further sensitization of parents and health community is important to reduce loss to follow-up.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×